Home › Encyclopedia › Linaclotide: Uses, Evidence, and Clinical Trial Data
Approved

Linaclotide: Uses, Evidence, and Clinical Trial Data

Molecular formulaC59H79N15O21S6
Molecular weight1526.8 g/mol
Registered trials62
PubChem CID16158208

What linaclotide is

Linaclotide is a peptide compound with the molecular formula C59H79N15O21S6 and a molecular weight of about 1,526.8 g/mol (PubChem CID 16158208). It is a cyclic peptide structure built from a sequence of amino acids linked by disulfide bonds. A specific product label was not available in this dataset, so details on approved indications, mechanism of action, and brand names are not covered here.

What the evidence shows

Linaclotide has been studied across 62 registered clinical trials. Among the available examples, a completed Phase 2 study evaluated 14 days of administration in patients meeting criteria for chronic constipation. A completed Phase 3 trial also examined linaclotide in patients with chronic constipation, and a separate completed study investigated its effects on brain and gut signaling in patients with IBS-C.

FAQ

Is linaclotide FDA approved?
This overview is based on trial registry and chemical identity data rather than a specific product label, so approved indications are not detailed here. Linaclotide has an extensive clinical trial history, including completed Phase 2 and Phase 3 studies.
What is linaclotide made of?
Linaclotide is a cyclic peptide with the molecular formula C59H79N15O21S6 and a molecular weight of approximately 1,526.8 g/mol. Its structure includes multiple disulfide bonds connecting a chain of amino acids.
How many clinical trials have studied linaclotide?
Linaclotide appears in 62 registered clinical trials. These include studies ranging from Phase 2 through Phase 3, as well as trials without a designated phase that examined physiological effects in specific patient populations.
What conditions has linaclotide been studied for?
Available trial examples show linaclotide studied in patients with chronic constipation and in patients with IBS-C (irritable bowel syndrome with constipation). One trial specifically examined its effect on brain and gut signaling pathways in IBS-C patients.
Are there side effect reports for linaclotide?
No adverse event report data was available in this dataset, so side effect patterns cannot be summarized here.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem ClinicalTrials.gov

Updated 2026-11-07